Trial Profile
A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys and Copegus versus Pegasys and Copegus alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Danoprevir (Primary) ; Ritonavir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms DAUPHINE
- Sponsors Roche
- 18 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 06 Jul 2012 Planned End Date changed from 1 Mar 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.